Programs
- Biomarker Data Repository (BmDR)
- Coalition For Accelerating Standards and Therapies (CFAST)
- Critical Path For Alzheimer's Disease (CPAD)
- Critical Path for Parkinson's (CPP)
- Critical Path to TB Drug Regimens (CPTR)
- Duchenne Regulatory Science Consortium (D-RSC)
- Data Collaboration Center (DCC)
- Electronic Patient-Reported Outcome Consortium (ePRO Consortium)
- Huntington’s Disease Regulatory Science Consortium (HD-RSC)
- International Neonatal Consortium (INC)
- Multiple Sclerosis Outcome Assessments Consortium (MSOAC)
- Polycystic Kidney Disease Outcomes Consortium (PKD)
- Patient-Reported Outcome Consortium (PRO Consortium)
- Predictive Safety Testing Consortium (PSTC)
- Pediatric Trials Consortium (PTC)
- Type 1 Diabetes Consortium (T1D)
- TB-Platform for Aggregation of Clinical TB Studies (TB-PACTS)
- Transplant Therapeutics Consortium (TTC)
Biomarker Data Repository
C-Path is developing a repository for data on novel translational safety biomarkers from drug development programs, with the goal of accelerating qualification of novel biomarkers as new tools for drug developers. This initial pilot focuses on kidney safety biomarkers.
Coalition For Accelerating Standards and Therapies
CFAST is an initiative formed in June 2012 to accelerate clinical research and medical product development by creating and maintaining data standards, tools and methods for conducting research in therapeutic areas that are important to public health.
Critical Path For Alzheimer's Disease
The Critical Path For Alzheimer’s Disease (CPAD) is a public-private partnership aimed at creating new tools and methods that can be applied to increase the efficiency of the development process of new treatments for Alzheimer disease (AD) and related neurodegenerative disorders with impaired cognition and function.
Critical Path for Parkinson's
Created in partnership with Parkinson’s UK, one of the world’s largest charity funders of Parkinson’s research, the Critical Path for Parkinson’s Consortium (CPP) was launched on October 14, 2015.
Critical Path to TB Drug Regimens
The CPTR initiative is dedicated to delivering a safer, more efficacious, and faster-acting tuberculosis (TB) regimen by developing and promoting innovative regulatory science essential for supporting new combination drug development in collaboration with its partners across industry, academia, and government.
Duchenne Regulatory Science Consortium
D-RSC supports collaborative research through shared data access and development of drug development tools.
Data Collaboration Center
Developing data solutions for scientific research.
Electronic Patient-Reported Outcome Consortium
The Electronic Patient-Reported Outcome (ePRO) Consortium provides scientific leadership and best practice recommendations surrounding electronic data capture technologies and services that support the collection of patient-focused outcomes data in clinical trials.
Huntington’s Disease Regulatory Science Consortium
Created in partnership with CHDI Foundation and the Critical Path Institute, HD-RSC was launched on March 28, 2018, with the aim of accelerating the regulatory approval of Huntington’s disease therapies.
International Neonatal Consortium
Launched on May 19, 2015, INC is C-Path’s ninth consortium – a global collaboration formed to forge a predictable regulatory path for evaluating the safety and effectiveness of therapies for neonates.
Multiple Sclerosis Outcome Assessments Consortium
Launched in December, 2012, MSOAC is another dynamic partnership formed to promote consensus science. Created jointly with the National Multiple Sclerosis Society, MSOAC will collect, standardize, and analyze data about MS with the goal of qualifying a new measure of disability as a primary or secondary endpoint for future trials of MS therapies.
Polycystic Kidney Disease Outcomes Consortium
C-Path's Polycystic Kidney Disease (PKD) Outcomes Consortium is a collaborative partnership whose research leads to discovery of treatments for PKD.
Patient-Reported Outcome Consortium
The Patient-Reported Outcome Consortium supports patient-focused drug development by obtaining qualification of clinical outcome assessment tools that measure how patients feel and function in their everyday lives as a result of treatment.
Predictive Safety Testing Consortium
C-Path's Predictive Safety Testing Consortium (PSTC) serves as a neutral third party in the independent assessment and validation of drug safety tests.
Pediatric Trials Consortium
PTC is committed to enabling the creation of a sustainable solution that assures the timely and efficient evaluation of innovative drugs, biologics and devices for children by delivering the regulatory-quality data needed for product labeling.
Type 1 Diabetes Consortium
The T1D Consortium is working to qualify islet autoimmunity antibodies as prognostic biomarkers to be used in the development of therapies for the treatment, and ultimately the prevention, of type 1 diabetes.
TB-Platform for Aggregation of Clinical TB Studies
The TB-PACTS data platform is designed to catalyze and accelerate TB research by curating and standardizing Phase III tuberculosis (TB) clinical trial data and making this data publicly available to qualified researchers.
Transplant Therapeutics Consortium
Co-founded by the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS), the Transplant Therapeutics Consortium (TTC) is a collaboration between the transplant community, industry, and regulatory agencies, and is managed and supported by Critical Path Institute (C-Path).
Creating and testing Alzheimer’s disease tools to facilitate drug development
Collaborating to develop instruments that measure the patient’s perspective
Developing and qualifying PRO instruments with the FDA for use in clinical trials
Qualifying biomarkers to identify patients for type 1 diabetes prevention clinical trials
Supporting collaborative research through shared data access and development of drug development tools
Bringing together experts with a range of skills to explore how patients view their therapy
Accelerating approval of Huntington’s therapeutics
Working with the FDA and medical product firms to assess patient outcomes
Collaborating to develop tools to accelerate drug development in transplantation
Developing standards for assessing outcomes in clinical trials of MS therapies
Qualifying instruments for use in clinical trials to evaluate treatment benefit
Enriching our understanding of the effect of interventions on how patients feel and function
Areas of Focus
-
Accelerating the path
-
Alzheimer’s Disease
-
Asthma
-
Data Collaboration
-
Depression
-
Diabetes
-
Drug Safety
-
Duchenne Muscular Dystrophy
-
Functional Dyspepsia
-
Huntington’s Disease
-
Irritable Bowel Syndrome
-
Kidney Transplant
-
Multiple Sclerosis
-
Non-Small Cell Lung Cancer
-
Parkinson’s Disease
-
Polycystic Kidney Disease
-
Rheumatoid Arthritis
-
Tuberculosis
Critical Path Institute, founded in 2005 in Tucson, Arizona, is an independent, nonprofit organization dedicated to bringing together experts from regulatory agencies, industry, and academia to collaborate and improve the medical product development process. More…
Past Events
-
Oct 30, 2018 Free Webinar – SOT Clinical and Translational Toxicology Specialty Section (CTTSS): Acetaminophen Induced Liver Toxicity: Mechanisms, Diagnosis and Treatment -
Oct 24, 2018 - Oct 27, 2018 11th Clinical Trials on Alzheimer’s Disease (CTAD) -
Oct 7, 2018 - Oct 10, 2018 9th Annual Conference of Pharmacometrics (ACoP9)
-
Jun 22, 2018 2018 Clinical Outcome Assessments in Cancer Clinical Trials Workshop -
Jun 6, 2018 Third Annual CPP Member Meeting 2018 -
May 10, 2018 Training on the Use of Technology to Collect Patient-Reported Outcome Data Electronically in Clinical Trials: Best Practice Recommendations from the ePRO Consortium (May 10, 2018)
Successes
- Qualification of drug-induced kidney injury (DIKI) clinical safety biomarker, composite measure
- C-Path’s PKDOC Secures EMA Qualification Opinion for Enrichment Biomarker in ADPKD
- C-Path’s PKDOC Secures FDA Qualification for Enrichment Biomarker in ADPKD
- Regulatory Support For Autosomal Dominant Polycystic Kidney Disease Biomarker
- C-Path Opportunities Table
- EMA Qualifies ‘Hollow Fiber System’ For Anti-Tuberculosis Drug Development
- FDA and EMA issue first-of-their-kind Letters of Support for two Kidney Biomarkers
- C-Path and CDISC partnership delivers therapeutic area standards
- C-Path’s Alzheimer’s Disease Simulator Featured in the Wall Street Journal
- FDA and EMA reach landmark decisions on C-Path’s Simulation Tool for Alzheimer’s disease
News
-
Nov 8, 2018 Profiles in Business with Tucson Metro Chamber -
Nov 5, 2018 Critical Path Institute Rebrands One of Its First Consortia to Highlight Focus on Alzheimer’s Disease -
Nov 1, 2018 C-Path Seeking Proposals for Qualitative Research and Preparation of Initial Briefing Package for Two COA Tools Documenting Treatment Benefit in Pediatric Asthma Patients -
Nov 1, 2018 C-Path, CHDI and CDISC Announce Therapeutic Area User Guide for Huntington’s Disease -
Oct 25, 2018 FNIH Biomarkers Consortium and Critical Path Institute Achieve the First Ever Qualification of a Clinical Safety Biomarker by the U.S. Food and Drug Administration -
Sep 25, 2018 UA Colleges of Law and Pharmacy, Critical Path Institute, Launch Graduate Certificate Program in Regulatory Science